These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21149617)

  • 1. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy.
    Bao BY; Pao JB; Huang CN; Pu YS; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Chen LM; Hsieh CJ; Huang SP
    Clin Cancer Res; 2011 Feb; 17(4):928-36. PubMed ID: 21149617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
    Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
    J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
    Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM
    J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reimbursement policy and androgen-deprivation therapy for prostate cancer.
    Shahinian VB; Kuo YF; Gilbert SM
    N Engl J Med; 2010 Nov; 363(19):1822-32. PubMed ID: 21047226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
    J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
    Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
    J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
    Aaronson D; Cowan J; Carroll P; Konety B
    BJU Int; 2010 Apr; 105(7):951-5. PubMed ID: 19889066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
    BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significance.
    Normand G; Celhay O; Briffaux R; Pirès C; Doré B; Fromont G; Irani J
    Urol Int; 2009; 83(2):160-5. PubMed ID: 19752610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.
    Holmes L; Chan W; Jiang Z; Du XL
    Prostate Cancer Prostatic Dis; 2007; 10(4):388-95. PubMed ID: 17486111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T; Maita S; Tsuchiya N; Ma Z; Narita S; Horikawa Y; Yamamoto S; Yonese J; Fukui I; Takahashi S; Hatake K; Habuchi T
    Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.